The present disclosure relates to a series of bis(hydroxymethyl) and its bis(carbamate) of 8H-3a-azacyclopenta[a]indene-1-yl and 5,10-dihydropyrrolo-[1,2-b]isoquinolines derivatives (Formula I-Formula IV) as DNA di-alkylating agents. The preliminary antitumor studies indicated that compounds disclosed herein could exhibit potent cytotoxicity in vitro and antitumor therapeutic efficacy in human tumor xenografts and could have little or no cross-resistance to either Taxol or Vinblastine. The results demonstrated that compounds disclosed herein possess potent antitumor therapeutic efficacy and are expected to have potential for clinical applications.
本公开涉及一系列8
H-3a-
氮杂
环戊二烯-1-基和5,10-二
氢吡咯并[1,2-b]
异喹啉衍
生物的双(
羟甲基)和其双(
氨基甲酸酯)(公式I-公式IV),作为DNA双烷基化剂。初步的抗肿瘤研究表明,本公开的化合物在体外可能表现出强大的细胞毒性,并在人类肿瘤移植物模型中表现出抗肿瘤治疗效果,并且可能几乎不会对
紫杉醇或
长春碱产生交叉耐药性。结果表明,本公开的化合物具有强大的抗肿瘤治疗效果,并有望在临床应用中发挥潜力。